A phase I, open-label study evaluating the safety, pharmacokinetics, and pharmacodynamic effects on de novo lipogenesis of the acetyl-CoA carboxylase inhibitor GS-0976 in healthy volunteers

Trial Profile

A phase I, open-label study evaluating the safety, pharmacokinetics, and pharmacodynamic effects on de novo lipogenesis of the acetyl-CoA carboxylase inhibitor GS-0976 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs GS 0976 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 17 Nov 2017 New trial record
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top